adjusted diluted net earnings per common share of $ 2.52 were up 140 % versus last year .
reported revenue was up 34 % , and core revenue grew 31 % .
this would include an estimated $ 2 billion of 2021 revenue at cytiva and pall biotech associated with vaccines and therapeutics , which is higher than our previous expectation of $ 1.3 billion .
our operating profit margin of 29.1 % was up 1,300 basis points year - over - year , including more than 900 basis points of core margin expansion as a result of higher gross margins and lower operating expenses as we continue to see limited travel and other related costs .
in response to the unprecedented demand for cepheid 's rapid point - of - care molecular test , the team again increased production capacity and shipped over 10 million respiratory test cartridges in the first quarter .
each of our largest operating companies in the platform achieved high single digit or better core revenue growth , led by cepheid , which achieved more than 90 % core revenue growth .
roughly half of the tests shipped were covid - only tests , and the other half were 4 - in - 1 combination test for covid - 19 flu a , flu b and rsv .
high - growth markets were up more than 45 % , largely driven by the recovery in china .
and at cepheid , we 'll continue ramping capacity through the year and now expect to ship approximately 45 million tests in 2021 compared to our prior estimate of 36 million tests .
between these four businesses , we 're investing more than $ 1 billion in 2021 to continue to meet our customers ' needs today and well into the future .
additionally , we expect to have operating profit fall - through of approximately 40 % in the second quarter and for the remainder of 2021 .
